- Lamia Tazi has lost $3.35 million as her 8.19% stake in Sothema dropped 5.21% over 12 days, reflecting market volatility.
- Sothemas stock has declined from MAD 1,055 ($108.87) to MAD 1,000 ($103.20) within 12 days, significantly impacting Tazi's investment.
- Despite short-term losses, Sothemas shares have increased by 7.25% year-to-date, showing overall resilience in Moroccos pharmaceutical market.
Lamia Tazi, a leading figure in Moroccos pharmaceutical industry, has seen a sharp decline in the value of her investment in Marocaine Ste de Therapeutique (Sothema), resulting in a $3.35 million loss. This downturn comes amid a broader slump in Sothema's share price, impacting Tazis substantial stake in the company.
Tazi, who holds an 8.19 percent stake in Sothema, equivalent to 589,658 shares, has seen her investment decline from MAD622.09 million ($64.20 million) on Sept. 10 to MAD589.66 million ($60.85 million) as of Sept. 22.
Over the past thirteen days, Sothema's stock has fallen by 5.21 percent, decreasing from MAD1,055 ($108.87) to MAD 1,000 ($103.20). This decline has resulted in a loss of MAD 32.43 million ($3.35 million) for Tazi.
Market challengesThe recent downturn is compounded by a more extensive loss that occurred between June 19 and July 16, when Tazi's holdings declined by $61.78 million, from MAD 607.35 million ($61.78 million) to MAD 563.12 million ($57.28 million). This significant decline raises questions about the sustainability of Sothema's growth amidst shifting market conditions.
Sothema, Moroccos leading healthcare company, manufactures approximately 60 million pharmaceutical units annually and has established partnerships with 35 multinational laboratories. The companys products are exported across Europe, the Maghreb, Sub-Saharan Africa, and the Persian Gulf, reflecting its pivotal role in the regional healthcare supply chain.
